Baidu is going to raise $2 billion within 3 years for a new biotechnology company, which will be a separate firm and not a subsidiary, reports CNBC citing sources. According to them, Baidu CEO Robin Lee personally participates in the biotechnology project. The new company will focus on using artificial intelligence and computer technology to create new drugs and diagnose diseases such as cancer in the early stages. Baidu has declined to comment.